• Connect with us
    • Information
      • About Us
      • Contact Us
      • Careers
      • Partnerships
      • Advertise With Us
      • Authors
      • Browse Topics
      • Events
      • Disclaimer
      • Privacy Policy
    • Australia
      North America
      World
    Login
    Investing News NetworkYour trusted source for investing success
    • North America
      Australia
      World
    • My INN
    Videos
    Companies
    Press Releases
    Private Placements
    SUBSCRIBE
    • Reports & Guides
      • Market Outlook Reports
      • Investing Guides
    • Button
    Resource
    • Precious Metals
    • Battery Metals
    • Base Metals
    • Energy
    • Critical Metals
    Tech
    Life Science
    Biotech Market
    Biotech News
    Biotech Stocks
    • Biotech Market
    • Biotech News
    • Biotech Stocks

    OTC Markets Group Welcomes BioCure Technology Inc. to OTCQB

    Investing News Network
    Jun. 18, 2018 07:45AM PST
    Biotech Investing
    Biotech Investing

    BioCure Technology Inc. (CSE:CURE, OTCQB:BICTF) (“BioCure” or the “Company”) begins trading on OTCQB under the symbol “BICTF.” U.S. investors can find current financial disclosure and Real-Time Level 2 quotes for the company on www.otcmarkets.com.

    BioCure Technology Inc. (CSE:CURE, OTCQB:BICTF) (“BioCure” or the “Company”) begins trading on OTCQB under the symbol “BICTF.” U.S. investors can find current financial disclosure and Real-Time Level 2 quotes for the company on www.otcmarkets.com.

    Trading on OTCQB will enable BioCure Technology Inc. to efficiently provide U.S. investors with current information. The Company is aiming to expand its U.S investor base and OTCQB will provide a greater visibility with U.S investors. This will allow the Company to provide greater transparency to the current and future shareholders in that market.

    About Biocure Technology Inc.

    Biocure is a South Korean-based biopharmaceutical company specializing in the development and potential commercialization of biosimilar pharmaceutical products. Biocure is in the process of preclinical trials of five major biosimilar products in South Korea, including interferon beta 1b, PEG-filgrastim and ranibizumab, as well as CAR-T-cell therapy. Biocure is also developing a foot and mouth disease vaccine, and, a hair growth production product.

    ON BEHALF OF THE BOARD OF DIRECTORS

    /s/ “Sang Mok Lee”

    CEO and Director

    For further information, please contact:

    Biocure Technology Inc. Telephone: 604-609-7149

    Certain statements in this news release, which are not historical in nature, constitute “forward looking statements” within the meaning of that phrase under applicable Canadian securities law. These statements include, but are not limited t —>o, statements or information concerning the Company’s proposed activities under the Agreement and the expectations of the Company regarding funding payments due pursuant to the Agreement. These statements reflect management’s current assumptions and expectations and by their nature are subject to certain underlying assumptions, known and unknown risks and uncertainties and other factors which may cause actual results, performance or events to be materially different from those expressed or implied by such forward looking statements. Except as required pursuant to applicable securities laws, the Company will not update these forward-looking statements to reflect events or circumstances after the date hereof. More detailed information about potential factors that could affect financial results is included in the documents filed from time to time with the Canadian securities regulatory authorities by the Company. Readers are cautioned not to place undue reliance on forward looking statements. Neither the Canadian Securities Exchange (the “CSE”) nor the Investment Industry Regulatory Organization of Canada) accepts responsibility for the adequacy or accuracy of this release.

    Click here to connect with BioCure Technology Inc. (CSE:CURE, OTCQB:BICTF) for an Investor Presentation.

    Source: www.stockwatch.com

    The Conversation (0)

    Go Deeper

    AI Powered
    Large pharmaceutical pill with gold dollar sign in the middle. Stock tickers and charts in the background.

    Top 5 Small-cap Pharma Stocks of 2025

    Row of test tubes and pipette with chemical droplet chemical coming from it.

    Top 5 Small-cap Biotech Stocks of 2025

    Latest News

    Outlook Reports

    Resource
    • Precious Metals
      • Gold
      • Silver
    • Battery Metals
      • Lithium
      • Cobalt
      • Graphite
    • Energy
      • Uranium
      • Oil and Gas
    • Base Metals
      • Copper
      • Nickel
      • Zinc
    • Critical Metals
      • Rare Earths
    • Industrial Metals
    • Agriculture
    Tech
      • Artificial Intelligence
      • Cybersecurity
      • Gaming
      • Cleantech
      • Emerging Tech
    Life Science
      • Biotech
      • Cannabis
      • Psychedelics
      • Pharmaceuticals

    Featured Biotech Investing Stocks

    More featured stocks

    Browse Companies

    Resource
    • Precious Metals
    • Battery Metals
    • Energy
    • Base Metals
    • Critical Metals
    Tech
    Life Science
    MARKETS
    COMMODITIES
    CURRENCIES
    ×